metaEvidence - overview


			deaths (OS)
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	dostarlimab plus soC vs. placebo plus SoC	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	durvalumab plus olaparib plus SoC vs. placebo plus SoC	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	durvalumab plus SoC vs. placebo plus SoC	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	pembrolizumab plus SoC vs. placebo plus SoC	2	-
versus Standard of Care (SoC)
	avelumab plus SoC vs. Standard of Care (SoC)	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	pembrolizumab plus lenvatinib vs. Standard of Care (SoC)	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)